Provided by Tiger Fintech (Singapore) Pte. Ltd.

Dare Bioscience

2.03
+0.00500.25%
Post-market: 2.040.0150+0.74%18:45 EDT
Volume:109.63K
Turnover:221.79K
Market Cap:27.30M
PE:-10.38
High:2.06
Open:2.05
Low:2.02
Close:2.02
52wk High:9.19
52wk Low:1.83
Shares:13.48M
Float Shares:13.34M
Volume Ratio:0.93
T/O Rate:0.82%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.1951
EPS(LYR):-0.4770
ROE:-994.69%
ROA:-63.13%
PB:-2.14
PE(LYR):-4.24

Loading ...

Apr 01, 2020

Beneficial Ownership Change

[Amend] General statement of acquisition of beneficial ownership
Mar 30, 2020

Employee Stock Ownership

S-8 - Securities to be offered to employees in employee benefit plans
Mar 27, 2020

Annual Report

10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
Mar 16, 2020

Major Issues Report

Current report, items 8.01 and 9.01
Feb 21, 2020

Beneficial Ownership Change

[Amend] General statement of acquisition of beneficial ownership
Feb 12, 2020

Beneficial Ownership Change

Statement of acquisition of beneficial ownership by individuals
Feb 10, 2020

Major Issues Report

Current report, items 8.01 and 9.01
Feb 06, 2020

Major Issues Report

Current report, items 8.01 and 9.01
Feb 05, 2020

Major Issues Report

Current report, item 8.01
Jan 30, 2020

Major Issues Report

[Amend] Current report, item 9.01
Jan 30, 2020

Major Issues Report

Current report, items 8.01 and 9.01
Jan 13, 2020

Major Issues Report

Current report, items 1.01, 7.01, and 9.01
Jan 09, 2020

Major Issues Report

Current report, items 8.01 and 9.01
Dec 26, 2019

Major Issues Report

Current report, item 3.01
Dec 09, 2019

Beneficial Ownership Change

[Amend] General statement of acquisition of beneficial ownership
Nov 22, 2019

Major Issues Report

Current report, item 3.01
Nov 21, 2019

Major Issues Report

Current report, items 2.01, 3.02, 5.02, 7.01, and 9.01
Nov 12, 2019

Major Issues Report

Current report, items 1.01, 3.02, 7.01, and 9.01
Nov 12, 2019

Quarterly Report

Quarterly report [Sections 13 or 15(d)]
Oct 02, 2019

Major Issues Report

Current report, items 8.01 and 9.01